Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial.

Trial Profile

Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Untreated CLL/SLL The HiLOG Trial.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Lenalidomide; Methylprednisolone; Sargramostim
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms HiLOG
  • Most Recent Events

    • 17 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
    • 17 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top